<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03065868</url>
  </required_header>
  <id_info>
    <org_study_id>KNUMC_15-1045</org_study_id>
    <nct_id>NCT03065868</nct_id>
  </id_info>
  <brief_title>Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp</brief_title>
  <official_title>Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp (Randomized Controlled Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyungpook National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the effect of H. pylori eradication on regression of H. pylori-related gastric&#xD;
      polyp (Ranomized controlled trial)&#xD;
&#xD;
        1. Study design: open labeled RCT&#xD;
&#xD;
        2. Study group H. pylori eradication group (N=17), non-eradication group (N=15)&#xD;
&#xD;
        3. Treatment plan&#xD;
&#xD;
             1. Baseline EGD&#xD;
&#xD;
                : 0.3-1cm sized polyp - bx &amp; CLO test (antrum &amp; body)&#xD;
&#xD;
                ==&gt; if H. pylori positive and eligible patients, randomization&#xD;
&#xD;
             2. Triple therapy&#xD;
&#xD;
             3. UBT (4week after eradication)&#xD;
&#xD;
             4. Follow-up EGD: gross finding, CLO test&#xD;
&#xD;
        4. Evaluation of polyp regression&#xD;
&#xD;
             1. disappear&#xD;
&#xD;
             2. regression over 50% (size, number)&#xD;
&#xD;
             3. no change or increase (size, number)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      (A) Study population&#xD;
&#xD;
        1. inclusion HP-realetd polyp polyp size with 0.3cm-1cm 20 yr - 70yr&#xD;
&#xD;
        2. exclusion peptic ulcer, healing stage or acute stage recent use of PPI within 4weeks&#xD;
           Liver cirrhosis, renal insufficiency, other serious chronic or acute disease current&#xD;
           infection of other bacteria, virus, or fungus cancer, psychologic disease heavy drinker&#xD;
           drug abuser pregnant women, Penicillin allergy, digoxin, antifungal, wafarin previosu H.&#xD;
           pylori eradication enroll gastric polyp with bleeding or malignant transformation tiny&#xD;
           polyp less than 3mm.&#xD;
&#xD;
      (B) Study method&#xD;
&#xD;
        1. Study design: open labeled RCT&#xD;
&#xD;
        2. Study group H. pylori eradication group (N=17), non-eradication group (N=15)&#xD;
&#xD;
        3. Treatment plan&#xD;
&#xD;
             1. Baseline EGD: 0.3-1cm sized polyp - bx &amp; CLO test (antrum &amp; body) ==&gt; if H. pylori&#xD;
                positive and eligible patients, randomization&#xD;
&#xD;
             2. Triple therapy&#xD;
&#xD;
             3. UBT (4week after eradication) if eradication failure in triple therapy, 2nd line&#xD;
                treatment (metroniazole based quadraple therpay) and the UBT (4week after&#xD;
                eradication)&#xD;
&#xD;
             4. Follow-up EGD (3-9M): gross finding, CLO test&#xD;
&#xD;
        4. Evaluation of polyp regression&#xD;
&#xD;
             1. disappear&#xD;
&#xD;
             2. regression over 50% (size, number)&#xD;
&#xD;
             3. no change or increase (size, number)&#xD;
&#xD;
        5. Statistical analysis&#xD;
&#xD;
             1. Chi-square test to compare polyp regression between treatment &amp; control group.&#xD;
&#xD;
             2. t-test to compare continuous variables between treatment &amp; control group.&#xD;
&#xD;
             3. Paired T-test to compare the size between baseline and follow-up EGD.&#xD;
&#xD;
             4. Regression analysis: univariate &amp; multivariate analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 9, 2015</start_date>
  <completion_date type="Actual">April 30, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open labelled randomized controlled trial. randomization : 2015 September</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare regression rate of gastric polyps between H. pylori eradication and non-eradication groups. Regression of gastric polyp: one of below 1) Disappearance of gastric polyp 2) Reduction of polyp size over 50%</measure>
    <time_frame>up to 24months</time_frame>
    <description>Evaluation of the effect of H. pylori eradication on the regression of H. pylori associated gastric polyp&#xD;
Study group&#xD;
H. pylori eradication&#xD;
H. pylori non-eradication&#xD;
Definition of gastric polyp change:&#xD;
Disappearance of gastric polyp&#xD;
Reduction of polyp size over 50%&#xD;
No change of size or increased size</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Gastric Polyp</condition>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>eradictaion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H. pylori eradication group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-eradication</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>H. pylori non-eradication group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)</intervention_name>
    <description>H. pylori eradication (Triple Therapy) as first line treatment if eradication failure, quadruple therpy will be provided as 2nd line treatment</description>
    <arm_group_label>eradictaion</arm_group_label>
    <other_name>Triple Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gastric polyp with current infection of H. pylori&#xD;
&#xD;
          -  Gastric polyp size with 3mm-10mm&#xD;
&#xD;
          -  Age of 20 yr - 70yr&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gastric ulcer ir duodenal ulcer (healing stage or acute stage)&#xD;
&#xD;
          -  Use of PPI within 4weeks&#xD;
&#xD;
          -  Liver cirrhosis, renal insufficiency, other serious chronic or acute disease&#xD;
&#xD;
          -  Current infection of other bacteria, virus, or fungus&#xD;
&#xD;
          -  Any cancer, psychologic disease&#xD;
&#xD;
          -  Heavy drinker&#xD;
&#xD;
          -  Drug abuser&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Penicillin allergy&#xD;
&#xD;
          -  Use of digoxin, antifungal, wafarin&#xD;
&#xD;
          -  Previous H. pylori eradication&#xD;
&#xD;
          -  Gastric polyp with bleeding or malignant transformation&#xD;
&#xD;
          -  Tiny polyp less than 3mm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Su Youn Y Nam, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Su Youn Nam</name>
      <address>
        <city>Daegu</city>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 18, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyungpook National University Chilgok Hospital</investigator_affiliation>
    <investigator_full_name>Su Youn Nam</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <keyword>gastric polyp</keyword>
  <keyword>Helicobacter pylori eradication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

